Display Settings:

Format
Sort by

Send to:

Choose Destination

    Results: 4

    1.

    Diabetic retinopathy: current management and experimental therapeutic targets.

    Ali TK, El-Remessy AB.

    Pharmacotherapy. 2009 Feb;29(2):182-92. Review.PMID: 19170588 [PubMed - indexed for MEDLINE]Related articles

    2.

    Poly(ADP-ribose)polymerase inhibition counteracts cataract formation and early retinal changes in streptozotocin-diabetic rats.

    Drel VR, Xu W, Zhang J, Kador PF, Ali TK, Shin J, Julius U, Slusher B, El-Remessy AB, Obrosova IG.

    Invest Ophthalmol Vis Sci. 2009 Apr;50(4):1778-90. Epub 2008 Dec 20.PMID: 19098320 [PubMed - indexed for MEDLINE]Related articles

    3.

    Aldose reductase inhibitor fidarestat counteracts diabetes-associated cataract formation, retinal oxidative-nitrosative stress, glial activation, and apoptosis.

    Drel VR, Pacher P, Ali TK, Shin J, Julius U, El-Remessy AB, Obrosova IG.

    Int J Mol Med. 2008 Jun;21(6):667-76.PMID: 18506358 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Peroxynitrite mediates retinal neurodegeneration by inhibiting nerve growth factor survival signaling in experimental and human diabetes.

    Ali TK, Matragoon S, Pillai BA, Liou GI, El-Remessy AB.

    Diabetes. 2008 Apr;57(4):889-98. Epub 2008 Feb 19.PMID: 18285558 [PubMed - indexed for MEDLINE]Related articlesFree article

    Supplemental Content

    Find related data

    Search details

    » See more...